Phaseline

Companies › Lupin

Lupin: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mexiletine
Sodium channel alpha subunit blocker
Ion channelsPhase 3Myotonia; Myotonic Dystrophy; Spinal and Bulbar Muscular AtrophyJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07097701MexiletinePhase 3MyotoniaNeurologyJan 2027
NCT06523400MexiletinePhase 3Myotonic DystrophyNeurologyJun 2027
NCT06862596MexiletinePhase 2Spinal and Bulbar Muscular AtrophyNeurologyDec 2027

From the company's SEC filings

Complete response letters from FDA

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Stoke Therapeutics Sandoz Merz Pharmaceuticals Neurona Therapeutics Actio Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.